Pancreatic Cancer: Pathobiology, Treatment Options, and Drug Delivery
Open Access
- 3 March 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in The AAPS Journal
- Vol. 12 (2), 223-232
- https://doi.org/10.1208/s12248-010-9181-5
Abstract
No abstract availableKeywords
This publication has 112 references indexed in Scilit:
- Tumor-Penetrating Microparticles for Intraperitoneal Therapy of Ovarian CancerJournal of Pharmacology and Experimental Therapeutics, 2008
- Molecular targeted therapies for pancreatic cancerThe American Journal of Surgery, 2008
- Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO studyAnnals Of Oncology, 2008
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature, 2006
- A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancerBritish Journal of Cancer, 2006
- Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsivenessProceedings of the National Academy of Sciences, 2006
- Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapyNature Reviews Cancer, 2006
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences, 2003
- Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cellNature Medicine, 1997